Current Report Filing (8-k)
October 22 2018 - 4:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 16, 2018
ALTIMMUNE, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-32587
|
|
20-2726770
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
910 Clopper Road, Suite 201S
Gaithersburg, Maryland
|
|
|
|
20878
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrants telephone number including area code: (240)
654-1450
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On October 16, 2018, William J. Enright notified the Board of
Directors (the Board) of Altimmune, Inc. (the Company) that he intends to resign as President and Chief Executive Officer (CEO) of the Company and as a member of the Board. The Board has begun a process to
identify Mr. Enrights successor. The Company and Mr. Enright have agreed that Mr. Enright will remain the President and CEO of the Company until the earlier of the appointment of his successor or February 28, 2019.
Mr. Enright will also remain on the Board until his resignation as President and CEO is effective. Mr. Enright stated that his decision to resign involved a disagreement over the scope of his responsibilities at the Company, but is not
otherwise the result of any disagreement with the Company on any matters relating to the Companys operations, policies or practices.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
ALTIMMUNE, INC.
|
|
|
By:
|
|
/s/ William Brown
|
|
|
Name: William Brown
|
|
|
Title: Acting Chief Financial Officer
|
Dated October 22, 2018
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2023 to Apr 2024